StockData
Spero Therapeutics, Inc. logo

Spero Therapeutics, Inc. (SPRO) stock

SPRONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 11/3045% below fair value
$0.90−0.05 (-4.77%)

Close on Nov 17, 2026Market cap $52.49MP/E 22.5Yield –

Spero Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Spero Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $47.00M, down 3.3% year over year. For fiscal 2025 it was $66.80M, up 39.2% from the year before. The highest annual figure on record is $103.78M in fiscal 2023.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$66.80M+39.2%
FY2024Dec 31, 2024$47.98M-53.8%
FY2023Dec 31, 2023$103.78M+94.0%
FY2022Dec 31, 2022$53.51M+193.1%
FY2021Dec 31, 2021$18.26M+95.7%
FY2020Dec 31, 2020$9.33M-48.6%
FY2019Dec 31, 2019$18.15M+357.6%
FY2018Dec 31, 2018$3.97M+100.4%
FY2017Dec 31, 2017$1.98M+490.7%
FY2016Dec 31, 2016$335.00K–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$0-100.0%
Q1 FY2026Mar 31, 2026$258.00K-95.6%
Q4 FY2025Dec 31, 2025$41.30M+174.5%
Q3 FY2025Sep 30, 2025$5.44M-59.6%
Q2 FY2025Jun 30, 2025$14.19M+39.1%
Q1 FY2025Mar 31, 2025$5.87M-36.6%
Q4 FY2024Dec 31, 2024$15.04M-79.5%
Q3 FY2024Sep 30, 2024$13.47M-47.1%
Q2 FY2024Jun 30, 2024$10.20M+275.4%
Q1 FY2024Mar 31, 2024$9.27M+347.9%
Q4 FY2023Dec 31, 2023$73.52M+55.0%
Q3 FY2023Sep 30, 2023$25.47M+1169.8%
Q2 FY2023Jun 30, 2023$2.72M+36.3%
Q1 FY2023Mar 31, 2023$2.07M0.0%
Q4 FY2022Dec 31, 2022$47.44M+1628.9%
Q3 FY2022Sep 30, 2022$2.01M-34.5%
Q2 FY2022Jun 30, 2022$1.99M-61.3%
Q1 FY2022Mar 31, 2022$2.07M-71.7%
Q4 FY2021Dec 31, 2021$2.74M+43.9%
Q3 FY2021Sep 30, 2021$3.06M-23.3%
Q2 FY2021Jun 30, 2021$5.15M+198.1%
Q1 FY2021Mar 31, 2021$7.30M+329.2%
Q4 FY2020Dec 31, 2020$1.91M+174.0%
Q3 FY2020Sep 30, 2020$4.00M-14.0%
Q2 FY2020Jun 30, 2020$1.73M-19.9%
Q1 FY2020Mar 31, 2020$1.70M-78.0%
Q4 FY2019Dec 31, 2019$696.00K-58.9%
Q3 FY2019Sep 30, 2019$4.64M+605.6%
Q2 FY2019Jun 30, 2019$2.16M+365.7%
Q1 FY2019Mar 31, 2019$7.72M+569.4%
Q4 FY2018Dec 31, 2018$1.69M+70.4%
Q3 FY2018Sep 30, 2018$658.00K+10.2%
Q2 FY2018Jun 30, 2018$463.00K+85.9%
Q1 FY2018Mar 31, 2018$1.15M+723.6%
Q4 FY2017Dec 31, 2017$993.00K–
Q3 FY2017Sep 30, 2017$597.00K–
Q2 FY2017Jun 30, 2017$249.00K–
Q1 FY2017Mar 31, 2017$140.00K–

More Spero Therapeutics figures

See a number that looks wrong?